Title: PROGNOSTIC VALUE OF COMORBIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY

Mobina Fathi1#, Kimia Vakili1#, Fatemeh Sayehmiri2, Ashraf Mohamadkhani3, Mohammadreza Hajiesmaeili4, Mostafa Rezaei-Tavirani5, Owrang Eilami6
# These authors contributed equally to the manuscript.

1. Student research committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2. Student research committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3. Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. Anesthesiology Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5. Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
6. Associate professor of Infectious disease, Department of Family Medicine, Shiraz University of Medical Science, Fars, IR. Visitant professor of University of Sao Paulo

Correspondence Authors:

Mohammadreza Hajiesmaeili, MD
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
P.O. Box: 1333635445,
Tel: +98-2151025343,
Fax: +98-2155424040,
E-mail: mrhajiesmaeili@sbmu.ac.ir

Mostafa Rezaei-Tavirani PhD
Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
TelFax: +98 21-22439847
Email: tavirany@yahoo.com

Running title: PROGNOSTIC VALUE OF COMORBIDITY FOR SEVERITY OF COVID-19

Abstract

Background & Aim: With the increase in the number of COVID-19 infections, global health is facing insufficient sources; this study aimed to provide additional data regarding the clinical characteristics of patients diagnosed with COVID-19 and in particular to analyze the factors associated with disease severity, unimprovement and mortality.

Methods: 82 studies were included in the present meta-analysis that all of them have been published before May 1, 2020 and were found by searching through the databases Scopus and MEDLINE. The selected papers were studied and analyzed by employing the version 14 of stata software. It should be noted that, we employed I² statistics for testing and verifying heterogeneity.
Results: 82 papers were finally chosen for this meta-analysis, including 74855 infected patients (35673 men, 31140 women). The mean age of the patients was 56.49. The results indicate the prevalence of fever 79.84 (95% CI: 75.22-84.13), cough 59.53 (95% CI: 55.35-63.65), fatigue or myalgia 33.46 (95% CI: 28.68-38.40), dyspnea 31.48 (95% CI: 25.75-37.49) and diarrhea 10.71 (95% CI: 8.20-13.49). The prevalence of the most common comorbidities were hypertension 25.10 (95% CI: 19.91-30.64), diabetes 13.48 (95% CI: 10.61-16.62), cardiovascular diseases 8.94 (95% CI: 6.99-11.10), and chronic kidney disease 3.27 (95% CI: 2.22-4.47).

Conclusion: The results of this study are seriously needed to effectively monitor the health of people with comorbidities (hypertension, diabetes, cardiovascular and cerebrovascular disease, coronary heart disease, and chronic kidney disease) to prevent the development of COVID-19 infection.

Keywords: meta-analysis, hypertension, diabetes, cardiovascular disease, comorbidity

Highlights:

- The most prevalent risk factors among patients with COVID-19 were hypertension, diabetes, cardiovascular disease, and chronic kidney disease.
- The most common symptoms among individuals who had COVID-19 infection were fever, cough, fatigue or myalgia, dyspnea, and diarrhea.
- The mean age of the patients with COVID-19 infection was 56.49.
- If the patient is an elderly male with underlying diseases, he is more likely to have severe disorders or even face to death.

Background

On December 31, 2019, a cluster of cases of pneumonia with an unknown source was reported in Wuhan, China, related to the Huanan seafood wholesale market (1, 2). Subsequently, on January 9, 2020, the China Center for Disease Control and Prevention announced its causative factor as novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This global disorder, caused by SARS-CoV-2, has been named COVID-19. Just two months later, on March 11, 2020, the Director General of the World Health Organization (WHO) announced the spread of COVID-19 as a pandemic disease (3, 4).

As of May 26, 2020, a total of 5,404,512 patients with confirmed COVID-19 infection and 343,514 dead cases have been reported by WHO globally and as of the time of this writing, its number is increasing. In addition, 216 countries, areas or territories with cases of COVID-19 infection have currently been discovered worldwide (5). As the number of COVID-19 infected patients is increasing worldwide and, due to its correlation with a huge morbidity and mortality rate, it has caused a new global phobia called Coro-phobia (6). According to the
results, COVID-19 infection could be diagnosed through several symptoms such as cough, fever, fatigue, diarrhea, myalgia and dyspnea (7-9).

Huang et al. evaluated the clinical features of 41 cases who had COVID-19 infection, and their result showed that 13 (32%) of them had comorbidities comprising; hypertension, chronic obstructive pulmonary disease, diabetes, and cardiovascular disease (10). In addition, W. Guan al. reported the results of 1099 cases of COVID-19 infection and their outcome showed that 261 (23.7%) of them had underlying diseases (11). These studies and similar investigations show that the complications can be considered a risk factor for harmful outcomes in patients with COVID-19 infection (12).

Furthermore, Lai et al. (13) realized that the mortality rate was associated with the country's healthcare resources. But in many societies, the intensive care unit (ICU) and the invasive ventilator were not enough to treat critically infected patients. Consequently, clinical operators should consider the risk factors for critical diseases of COVID-19, correctly assign medical sources, identify severe patients in the early stages of the disease and adjust an appropriate treatment plan to reduce the mortality rate and improve the effectiveness of the treatment (14). Therefore, knowing the risk factors and underlying diseases in patients with COVID-19 infection is important for healthcare professionals and especially for immunocompromised people and the elderly. Subsequently, the evaluation of the prevalence of chronic diseases such as hypertension, kidney disease, cardiovascular disease and diabetes is considered as one of the most important activities to reduce the harmful outcomes in patients with COVID-19 infection (15).

Currently, we have no specific vaccines or curative drugs approved against the new COVID-19 infection, so to prevent COVID-19 infection, a systematic review and meta-analysis has been conducted on a study of the prevalence of common comorbidities by analysis of clinical risk factors resource for COVID-19.

**Methods**

**Study selection**

We searched PubMed and Scopus databases to obtain qualified studies that were published on COVID-19 until May 1, 2020. The keywords for our research included: Kidney, COVID, Hypertension, Diabetes, ((Heart) OR Cardio-), and Comorbidities. Their references were also searched in order to collect those that are related to the title.

**Inclusion and exclusion criteria**

All studies evaluating the clinical risk factors, underlying diseases and comorbidities of COVID-19 have been reviewed. For our final analysis, the studies selected should report data on the prevalence of each of the risk factors for the severity of COVID-19 and its comorbidities in patients with COVID-19 infection, including hypertension, chronic kidney disease, diabetes, cardiovascular and cerebrovascular diseases, and coronary...
heart disease. Only human investigations were selected. The full texts of the relevant documents were assessed for exclusion and inclusion criteria. Studies that did not have adequate data, non-human studies, duplicate publications and non-English publications (except those with useful abstract data) were excluded.

Data extraction

All the selected papers were independently evaluated and screened by two authors (M.F. and K.V.), and the disagreement was resolved through discussion. The following data were collected for the final analysis: prevalence of hypertension, chronic kidney disease, diabetes, cardiovascular and cerebrovascular diseases, and coronary heart disease and in addition the symptoms such as fever, dyspnea, diarrhea, cough, fatigue or myalgia. Since COVID-19 is a newly developed disorder and COVID-19 related studies are still ongoing, the quality of the selected studies has not been evaluated in our document.

Statistical analysis

Because of the effect size in this study was the proportion (prevalence of hypertension, chronic kidney disease, diabetes, cardiovascular and cerebrovascular diseases, coronary heart disease); binomial distribution was employed to calculate variance for each research. The prevalence of various researches was combined using the average weight. An inverse relationship between the variance of the study and its weight was observed. The $I^2$ index were being applied to evaluate the heterogeneity. In the case of heterogeneous studies, random effects model were used. To analyze data, STATA software (version 14) were used. The Metaprop (meta-analysis for proportion) was used in STATA and when $p$ was near to 0 or 1. For stabilizing the variances, we used Freeman-Tukey Double Arcsine Transformation (16). This paper was performed under the approval of ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1399.084).

Results

Research Selection

This study written according to PRISMA checklist (17). 151 studies were initially obtained through primary search on PubMed and 49 more articles were identified through Scopus. 41 of those 200 articles were excluded because of duplication. After screening the abstract and title of all searched papers, 47 more studies were excluded. the full text of 102 remaining studies was reviewed, 20 of them were excluded due to some reasons such as review article, case reports and short reports and insufficient data. Finally, 82 articles that have been published from February 2019 to April 2020, were selected for meta-analysis (Fig. 1, Table 1).

Demographic Characteristics
Evaluating all the data collected, the total number of hospitalized patients, including this analysis, was 74855 including 9678 patients with hypertension, 5722 patients with diabetes, 2454 patients with cardiovascular disease, 1030 patients with chronic kidney disease, 189 with coronary heart disease, 176 with cardiovascular and cerebrovascular diseases. According to results, the percentage of men was 54.26 (95% CI: 52.10-56.40; $I^2=92.33\%$) and women 45.82 (95% CI: 43.83-47.98; $I^2=92.37\%$) (Table 2). The mean age of the included study was 56.49. Most of our studies were conducted in China, except 4 in the United States, 2 in Italy, 2 in Korea, 1 in Bolivia and 1 in Singapore (Table 2). It is important to remember that 3 (18-20) of our chosen documents divided the sample size into two groups, so we considered them as 6 studies (Table 1). We should also note that 6 of the chosen studies have reported the number of patients with both cardiovascular and cerebrovascular disease not separately. Due to papers that reported the number of individuals who had a history of exposure, the prevalence of the total exposure history was also calculated 35.56 (95% CI: 21.97-50.38; $I^2=99.43\%$) (Table 2).

**Clinical Manifestations**

The results of this analysis indicates that the prevalence of the most prevalent symptoms of COVID-19 were fever 79.84 (95% CI: 75.22-84.13; $I^2=97.33\%$), cough 59.53 (95% CI: 55.35-63.65; $I^2=95.07\%$), fatigue or myalgia 33.46 (95% CI: 28.68-38.40; $I^2=96.29\%$), dyspnea 31.48 (95% CI: 25.75-37.49; $I^2=97.80\%$), and diarrhea 10.71 (95% CI: 8.20-13.49; $I^2=93.87\%$) (Table 2).

**Comorbidities**

In this systematic review, we focused on the prevalence of people with comorbidities 47.01% (95% CI: 35.03-59.16; $I^2=99.69\%$) (Table 2). The prevalence of the most common comorbidities is hypertension 25.10 (95% CI: 19.91-30.64; $I^2=99.24\%$) (Fig.2, Table 2), diabetes 13.48 (95% CI: 10.61-16.62; $I^2=98.73\%$) (Fig.3, Table 2), cardiovascular diseases 8.94 (95% CI: 6.99-11.10; $I^2=97.12\%$) (Fig.4, Table 2) and chronic kidney disease 3.27 (95% CI: 2.22-4.47; $I^2=93.22\%$) (Table 2), respectively. We also assessed the prevalence of some other comorbidities found in our included articles comprising: cardiovascular and cerebrovascular diseases 18.25 (95% CI: 7.47-32.11; $I^2=94.10\%$), and coronary heart disease 6.81 (95% CI: 4.20-9.91; $I^2=84.11\%$) (Table 2).

**Outcomes**

We calculated the percentage of the mortality rate based on all the studies reporting the case of mortality 15.01 (95% CI: 10.60-19.98; $I^2=99.21\%$). After removing 5 researches from our selected studies that were conducted only on deceased individuals, the overall mortality rate of the case was calculated from the remaining 55 studies 8.44 (95% CI: 5.86-11.38; $I^2=98.47\%$) (Table 2). After removing the studies that only assessed the deaths, a subgroup analysis was also performed to assess the prevalence of the mortality rate.
base on the place. As previously stated, 51 papers of our included studies were from China 7.35% (95% CI: 4.77-10.37; I²=98.20%), 4 of them from USA 8.89 (95% CI: 8.12-9.69), 1 from Bolivia 0.00 (95% CI: 0.00-26.46), and 1 from UK 74.26 (95% CI: 64.60-82.44) (Table 2).

**Publication Bias**

Figure 5. Shows the Beggs funnel plot of the comorbidity studies discussed in patients with COVID-19 infection. The interpretation of our Beggs funnel plot shows no sign of publication bias in included studies (p=0.240); therefore; it is understandable that reports have been published with both positive and negative outcomes (Figure 5.). Based on the results of Meta-regression analysis, the correlation between the prevalence and the sample size was compared, due to this assessment and figure, a significant relation was not observed between the prevalence and sample size (P = 0.428), also in the noted figure the circles indicate the weight of papers (Figure 6.).

**Discussion**

In December 2019, a new coronavirus disease outbreak, coronavirus disease 2019 (COVID-19), spread globally (21). The city of Wuhan in China is considered to be one of the most infected areas in the world (22). Due to this epidemic contagious disease, aggressive quarantine had been suggested by the government and also played an important role in monitoring the prevalence of this virus. COVID-19 is highly contagious and insidious, it also has the ability to give rise to cluster outbreaks (23, 24). The SARS-CoV-2 virus can attack certain cells in our body, in particular alveolar epithelial cells, by a specific enzyme which is named as angiotensin-converting enzyme 2 (ACE2). ACE2 is considered to be the ACE of the isoenzyme, mainly distributed in the testes, kidneys, colon, cardiovascular system, lungs and also in other organs (25).

Up to the date of this review, the pathogenesis and origin of COVID-19 has remained unknown and no useful medical treatment has been offered for COVID-19 infection. Recommendations insist on careful and supportive care to reduce the risk of infection with this SARS-CoV-2 virus (10, 26). Unfortunately, in severely ill patients who are infected with COVID-19, the disorder develops rapidly and acute respiratory distress syndrome (ARDS) as one of the worst complications of COVID-19 outcomes can occur earlier and even lead to death. In a research by Tian et al. (27), it was stated that the percentage of mild and seriously ill patients was 73% and 18% respectively. Furthermore, Wang et al. found that the risk of exacerbation in patients with cerebrovascular disease, hypertension, cardiovascular disease, or diabetes is higher than others (1).
This meta-analysis is based on data from 82 studies with laboratory-confirmed SARS-CoV-2. The selected studies were from all over the world not a specific region. Based on previous researches on SARS-CoV and MERS-CoV, it is understood that these viruses affect males more than females (28, 29). And also because of our results, men 54.26 (95% CI: 52.10-56.40; I² = 92.33%) are more affected with SARS-CoV-2 than women 45.82 (IC 95%: 43.83-47.98; I² = 92.37%), moreover, this may be due to their more adaptive innate immune and robust responses (30). Another reason for our findings may be that men have a tendency to have more relationships with harmful lifestyle habits such as the underlying diseases and smoking than women (14). Moreover, as mentioned in Huang’s report (1), this may be associated with the risk factors that are related to men’s occupations with the exposure of Huanan wet market. Furthermore, due to our results, aged people (mean age=56.49) are more prone to COVID-19 and this could be related to an increase in the frequency of the common comorbidities (31). As our body's immunity weakens with age, elderly patients are more likely to have serious ailments or even death (14).

Our study indicates the sensible evidence of risk factors in severely ill patients with COVID-19 infection, such as characteristics of the patients (gender, age), comorbidity (hypertension, chronic kidney disease, diabetes, cardiovascular and cerebrovascular diseases, and coronary heart disease) and signs and symptoms (fever, diarrhea, fatigue or myalgia and dyspnea) (32). Furthermore, we have discovered that underlying diseases such as diabetes, hypertension, cardiovascular disease, and chronic kidney disease can be considered as risk factors for the progression of this disorder. This statement conforms to the analytical results of our research. The common clinical symptoms of COVID-19 in infected patients are also fever, diarrhea, fatigue or myalgia and dyspnea and all of them have been assessed in this paper. Dyspnea or shortness of breath advises lack of oxygen and lung function. So if the patient is an elderly male with underlying diseases, he is more likely to have severe disorders or even face to death (14).

According to all of our assessed studies, we found that fever 79.84 (95% CI: 75.22-84.13; I²=97.33%) is the most common symptom and hypertension 25.10 (95% CI: 19.91-30.64; I²=99.24%) can considered as the most prevalent comorbidity. To compare our results with other recent meta-analysis studies, research conducted by Alfonso J. Rodriguez-Morales et al. (33), is evidence of our findings; they also found that fever 88.7% (95% CI 84.5–92.9) is the most prevalent symptom and hypertension 18.6 (95% CI 8.1–29.0) is most common comorbidity, however our studies were larger than they are and therefore, our findings are more reliable. Our findings will also be approved by a study by Jing Yang et al. (15), in which fever 91.3 (95% CI: 86–97) was the most prevalent symptom and hypertension 21.1 (95% CI: 13.0-27.2) was the most common comorbidty. Besides, like a recent study by Emami et al. (34), hypertension was known as the most prevalent comorbidity 16.37 (95% CI: 10.15-23.65). According to the prevalence of hypertension and diabetes in China, diabetes mellitus and hypertension accounted for 10.9% (35) and 23.2% (36) in adults.

Regarding the studies cited and our results, individuals with cardiovascular disease, hypertension, chronic kidney disease, and diabetes should receive serious attention for treatments and vaccinations useful for SARS-CoV-2 in the future. Due to limited evidence, more appropriate studies are needed to demonstrate this correlation (15).
In summary, the results of the current review indicated that in COVID-19 patients, diabetes, hypertension, cardiovascular disease, and chronic kidney disease are the most common comorbidities and fever, diarrhea, fatigue or myalgia and dyspnea may be considered as the most prevalent symptoms among patients with COVID-19 infection. As for the fact that SARS-CoV-2 has a long incubation period and even infected people can transmit this contagious virus without indicating obvious symptoms, it is seriously suggested that sick patients who have underlying disorders, especially in epidemic areas, refrain from coming into contact with other people in society. Additionally, other strategies such as avoiding gathering in public areas and going to epidemic places should be considered as guidelines. During the current COVID-19 outbreak, the reported statistics, which are related to overall mortality, incubation time, and in particular to risk factors, imply serious decisions for future prevention and therapeutic actions (34).

Conclusion

Due to the results of this meta-analysis, COVID-19 is notably associated with the underlying diseases. According to our results, the most frequent comorbidities among hospitalized patients with COVID-19 infection were hypertension, diabetes, cardiovascular disease and chronic kidney disease, respectively. We also found that an old man with underlying diseases is at high risk of becoming infected with COVID-19. Therefore; given the high risk of death in patients with COVID-19 infection, special care and significant attention is needed in patients suffering from COVID-19 infection with associated conditions.

Funding
None.

Acknowledgement
The authors of this study are thankful to Shahid Beheshti University of Medical Sciences, Tehran, IR Iran because of their collaboration.

Conflict of interest
None declared.

Abbreviations
World Health Organization: WHO; intensive care unit: ICU; angiotensin-converting enzyme 2: ACE2; No: Number

Declarations
Ethics approval and consent to participate
This paper was performed under the approval of ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1399.084).
Consent for publication
The authors agree with the publication of this article.

Availability of data and material
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Funding
None.

Authors’ contributions
Mobina Fathi: First idea, writing the manuscript, major role, editing draft
Kimia Vakili: First idea, writing the manuscript, major role, editing draft
Fatemeh Sayehmiri: Statistical analysis, major role, editing draft
Ashraf Mohamadkhani: scientific support
Mohammadreza Hajiesmaeili: supervision, scientific support
Mostafa Rezaei-Tavirani: supervision, scientific support
Owrang Eilami: editing draft

Acknowledgements
No.


Fig 1. Study flow diagram.

151 of records identified through database searching

49 of additional records identified through other sources

41 of records after duplicates removed

102 of records screened

102 of full-text articles assessed for eligibility

20 of full-text articles excluded, with reasons

82 of studies included in quantitative synthesis (meta-analysis)
Table 1. Baseline characteristics of studies included in this meta-analysis.

<table>
<thead>
<tr>
<th>Study</th>
<th>Place</th>
<th>Median age</th>
<th>Exposure setting (No.)</th>
<th>Patients (No.)</th>
<th>Symptoms (No.)</th>
<th>Comorbidities (No.)</th>
<th>Mortality rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(37)</td>
<td>China</td>
<td>56</td>
<td>73</td>
<td>191</td>
<td>9</td>
<td>72</td>
<td>2</td>
</tr>
<tr>
<td>(38)</td>
<td>China</td>
<td>3</td>
<td>85</td>
<td>62</td>
<td>23</td>
<td>78</td>
<td>3</td>
</tr>
<tr>
<td>(39)</td>
<td>China</td>
<td>57.00</td>
<td>140</td>
<td>71</td>
<td>69</td>
<td>110</td>
<td>2</td>
</tr>
<tr>
<td>(40)</td>
<td>China</td>
<td>59.00</td>
<td>174</td>
<td>76</td>
<td>98</td>
<td>136</td>
<td>2</td>
</tr>
<tr>
<td>(5)</td>
<td>China</td>
<td></td>
<td>1390</td>
<td>904</td>
<td>634</td>
<td>1351</td>
<td>2</td>
</tr>
<tr>
<td>(41)</td>
<td>China</td>
<td>51.00</td>
<td>979</td>
<td>128</td>
<td>73</td>
<td>188</td>
<td>2</td>
</tr>
<tr>
<td>(42)</td>
<td>China</td>
<td>69.00</td>
<td>379</td>
<td>166</td>
<td>133</td>
<td>311</td>
<td>2</td>
</tr>
<tr>
<td>(32)</td>
<td>China</td>
<td>73.00</td>
<td>25</td>
<td>10</td>
<td>15</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td>(43)</td>
<td>U.S</td>
<td></td>
<td>7162</td>
<td></td>
<td></td>
<td>2092</td>
<td>213</td>
</tr>
<tr>
<td>(44)</td>
<td>U.S</td>
<td></td>
<td>180</td>
<td></td>
<td></td>
<td>153</td>
<td>20</td>
</tr>
<tr>
<td>(45)</td>
<td>China</td>
<td>50.00</td>
<td>311</td>
<td>1012</td>
<td>488</td>
<td>761</td>
<td>2</td>
</tr>
<tr>
<td>(1)</td>
<td>China</td>
<td>49.00</td>
<td>47</td>
<td>30</td>
<td>11</td>
<td>40</td>
<td>14.63</td>
</tr>
<tr>
<td>(26)</td>
<td>China</td>
<td>56.00</td>
<td>12</td>
<td>138</td>
<td>75</td>
<td>136</td>
<td>11.00</td>
</tr>
<tr>
<td>(46)</td>
<td>China</td>
<td>47.00</td>
<td>1099</td>
<td>637</td>
<td>439</td>
<td>473</td>
<td>4</td>
</tr>
<tr>
<td>(47)</td>
<td>China</td>
<td>41.00</td>
<td>23</td>
<td>62</td>
<td>35</td>
<td>48</td>
<td>14.00</td>
</tr>
<tr>
<td>(31)</td>
<td>China</td>
<td>57.00</td>
<td>0</td>
<td>80</td>
<td>39</td>
<td>63</td>
<td>1</td>
</tr>
<tr>
<td>(48)</td>
<td>China</td>
<td>40.00</td>
<td>61</td>
<td>31</td>
<td>30</td>
<td>60</td>
<td>0.00</td>
</tr>
<tr>
<td>(5)</td>
<td>China</td>
<td>52.00</td>
<td>52</td>
<td>35</td>
<td>17</td>
<td>51</td>
<td>61.54</td>
</tr>
<tr>
<td>(51)</td>
<td>China</td>
<td>47.00</td>
<td>187</td>
<td>91</td>
<td>96</td>
<td>61</td>
<td>23.00</td>
</tr>
<tr>
<td>(52)</td>
<td>Italy</td>
<td></td>
<td>355</td>
<td></td>
<td></td>
<td>72</td>
<td>100.00</td>
</tr>
<tr>
<td>(53)</td>
<td>China</td>
<td>12</td>
<td>8</td>
<td>4</td>
<td>10</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>(54)</td>
<td>China</td>
<td>9</td>
<td>5</td>
<td>4</td>
<td>8</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>(55)</td>
<td>China</td>
<td>31974</td>
<td>44672</td>
<td>22981</td>
<td>21691</td>
<td>2683</td>
<td>2.30</td>
</tr>
<tr>
<td>(10)</td>
<td>China</td>
<td>38.00</td>
<td>0</td>
<td>79</td>
<td>39</td>
<td>34</td>
<td>8</td>
</tr>
<tr>
<td>(56)</td>
<td>China</td>
<td>63.00</td>
<td>701</td>
<td>367</td>
<td>334</td>
<td>213</td>
<td>14.16</td>
</tr>
<tr>
<td>(57)</td>
<td>China</td>
<td>57.00</td>
<td>193</td>
<td>95</td>
<td>98</td>
<td>171</td>
<td>66.32</td>
</tr>
<tr>
<td>(58)</td>
<td>China</td>
<td>62.00</td>
<td>274</td>
<td>171</td>
<td>103</td>
<td>249</td>
<td>41.24</td>
</tr>
<tr>
<td>(59)</td>
<td>China</td>
<td>72.50</td>
<td>82</td>
<td>54</td>
<td>28</td>
<td>64</td>
<td>12.80</td>
</tr>
<tr>
<td>(60)</td>
<td>China</td>
<td>5.00</td>
<td>5</td>
<td>1</td>
<td>5</td>
<td>5</td>
<td>0.00</td>
</tr>
<tr>
<td>(61)</td>
<td>China</td>
<td>64.00</td>
<td>416</td>
<td>205</td>
<td>211</td>
<td>334</td>
<td>52.40</td>
</tr>
<tr>
<td>(62)</td>
<td>China</td>
<td>54.00</td>
<td>116</td>
<td>67</td>
<td>49</td>
<td>43</td>
<td>3</td>
</tr>
<tr>
<td>(63)</td>
<td>US</td>
<td></td>
<td>21</td>
<td>11</td>
<td>11</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>(64)</td>
<td>China</td>
<td>54.00</td>
<td>203</td>
<td>108</td>
<td>95</td>
<td>181</td>
<td>12.80</td>
</tr>
<tr>
<td>(65)</td>
<td>China</td>
<td>50.00</td>
<td>91</td>
<td>37</td>
<td>54</td>
<td>65</td>
<td>0.00</td>
</tr>
<tr>
<td>(66)</td>
<td>China</td>
<td>58.00</td>
<td>452</td>
<td>255</td>
<td>217</td>
<td>423</td>
<td>36.70</td>
</tr>
<tr>
<td>Country</td>
<td>Price</td>
<td>Code</td>
<td>69</td>
<td>32</td>
<td>37</td>
<td>30</td>
<td>38</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>China</td>
<td>55.00</td>
<td>8</td>
<td>221</td>
<td>108</td>
<td>113</td>
<td>200</td>
<td>136</td>
</tr>
<tr>
<td>Italy</td>
<td>63.00</td>
<td></td>
<td>1591</td>
<td>1304</td>
<td>287</td>
<td>1043</td>
<td>509</td>
</tr>
<tr>
<td>US</td>
<td>63.00</td>
<td></td>
<td>5700</td>
<td>3437</td>
<td>2263</td>
<td>5700</td>
<td>3026</td>
</tr>
<tr>
<td>China</td>
<td>54.00</td>
<td>47</td>
<td>102</td>
<td>53</td>
<td>49</td>
<td>83</td>
<td>50</td>
</tr>
<tr>
<td>China</td>
<td>50.00</td>
<td>54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>54.00</td>
<td>110</td>
<td>60</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>51.00</td>
<td>149</td>
<td>52</td>
<td>48</td>
<td>36</td>
<td>54</td>
<td>43</td>
</tr>
<tr>
<td>China</td>
<td>55.00</td>
<td>109</td>
<td>59</td>
<td>50</td>
<td>90</td>
<td>67</td>
<td>62</td>
</tr>
<tr>
<td>China</td>
<td>64.91</td>
<td></td>
<td>652</td>
<td>349</td>
<td>303</td>
<td>521</td>
<td>423</td>
</tr>
<tr>
<td>China</td>
<td>60.00</td>
<td>548</td>
<td>279</td>
<td>269</td>
<td>476</td>
<td>415</td>
<td>258</td>
</tr>
<tr>
<td>China</td>
<td>52.00</td>
<td>113</td>
<td>66</td>
<td>47</td>
<td>91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>60.00</td>
<td>27</td>
<td>12</td>
<td>15</td>
<td>21</td>
<td>16</td>
<td>3</td>
</tr>
<tr>
<td>China</td>
<td>136</td>
<td>58</td>
<td>78</td>
<td>115</td>
<td>85</td>
<td>24</td>
<td>17</td>
</tr>
<tr>
<td>China</td>
<td>652</td>
<td>349</td>
<td>303</td>
<td>521</td>
<td>423</td>
<td>115</td>
<td>20</td>
</tr>
<tr>
<td>China</td>
<td>39.00</td>
<td>12</td>
<td>6</td>
<td>6</td>
<td>9</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>China</td>
<td>45.00</td>
<td>104</td>
<td>161</td>
<td>80</td>
<td>81</td>
<td>122</td>
<td>103</td>
</tr>
<tr>
<td>China</td>
<td>47.00</td>
<td>113</td>
<td>135</td>
<td>72</td>
<td>63</td>
<td>120</td>
<td>102</td>
</tr>
<tr>
<td>China</td>
<td>37</td>
<td>14</td>
<td>23</td>
<td>15</td>
<td>12</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>China</td>
<td>214</td>
<td>87</td>
<td>127</td>
<td>132</td>
<td>107</td>
<td>41</td>
<td>83</td>
</tr>
<tr>
<td>China</td>
<td>65.00</td>
<td>112</td>
<td>57</td>
<td>55</td>
<td>98</td>
<td>79</td>
<td>63</td>
</tr>
<tr>
<td>China</td>
<td>136</td>
<td>90</td>
<td>46</td>
<td>52</td>
<td>71</td>
<td>66</td>
<td>27</td>
</tr>
<tr>
<td>China</td>
<td>70.00</td>
<td>25</td>
<td>19</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea</td>
<td>51.00</td>
<td>149</td>
<td>60</td>
<td>89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>47.00</td>
<td>18</td>
<td>9</td>
<td>13</td>
<td>15</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Korea</td>
<td>75.50</td>
<td>54</td>
<td>33</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>92</td>
<td>49</td>
<td>43</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>168</td>
<td>86</td>
<td>82</td>
<td>156</td>
<td>121</td>
<td>65</td>
<td>44</td>
</tr>
<tr>
<td>China</td>
<td>13</td>
<td>10</td>
<td>3</td>
<td>13</td>
<td>10</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>China</td>
<td>12</td>
<td>2</td>
<td>10</td>
<td>11</td>
<td>7</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>UK</td>
<td>82.00</td>
<td>101</td>
<td>64</td>
<td>37</td>
<td>9</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>China</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>China</td>
<td>134</td>
<td>149</td>
<td>81</td>
<td>68</td>
<td>114</td>
<td>87</td>
<td>11</td>
</tr>
<tr>
<td>Korea</td>
<td>31</td>
<td>81</td>
<td>42</td>
<td>39</td>
<td>59</td>
<td>48</td>
<td>7</td>
</tr>
<tr>
<td>Korea</td>
<td>77.00</td>
<td>66</td>
<td>37</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 2. Statistical analysis of reviewed articles

<table>
<thead>
<tr>
<th>Number of study</th>
<th>Prevalence (%)</th>
<th>95% CI</th>
<th>P(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>79</td>
<td>54.26</td>
<td>(52.10-56.40)</td>
</tr>
<tr>
<td>female</td>
<td>79</td>
<td>45.82</td>
<td>(43.67-47.98)</td>
</tr>
<tr>
<td><strong>Exposure history</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>21</td>
<td>35.56</td>
<td>(21.97-50.38)</td>
</tr>
<tr>
<td>Cough</td>
<td>66</td>
<td>59.53</td>
<td>(55.35-63.65)</td>
</tr>
<tr>
<td>Fatigue or Myalgia</td>
<td>56</td>
<td>33.46</td>
<td>(28.68-38.40)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>56</td>
<td>31.48</td>
<td>(25.75-37.49)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>52</td>
<td>10.71</td>
<td>(8.20-13.49)</td>
</tr>
<tr>
<td><strong>Comorbidity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>75</td>
<td>25.10</td>
<td>(19.91-30.64)</td>
</tr>
<tr>
<td>Cardiovascular and cerebrovascular diseases</td>
<td>6</td>
<td>18.25</td>
<td>(7.47-32.11)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>77</td>
<td>13.48</td>
<td>(10.61-16.62)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>44</td>
<td>3.27</td>
<td>(2.22-4.47)</td>
</tr>
<tr>
<td><strong>Heart diseases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>51</td>
<td>8.94</td>
<td>(6.99-11.10)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>14</td>
<td>6.81</td>
<td>(4.20-9.91)</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality in China</td>
<td>51</td>
<td>7.35</td>
<td>(4.77-10.37)</td>
</tr>
<tr>
<td>Mortality in USA</td>
<td>2</td>
<td>8.89</td>
<td>(8.12-9.69)</td>
</tr>
<tr>
<td>Mortality in Bolivia</td>
<td>1</td>
<td>0.00</td>
<td>(0.00-26.46)</td>
</tr>
<tr>
<td>Mortality in UK</td>
<td>1</td>
<td>74.26</td>
<td>(64.60-82.44)</td>
</tr>
</tbody>
</table>
Fig 2. Forest Plot of the prevalence of hypertension in COVID-19 patients.
Each square indicates the effect estimate of individual articles with their 95% CI. Size of squares is proportional to the weight of each paper in the meta-analysis. In this plot, papers are indicated in the order of first author’s names and publication date (based on a random effects model).
Each square indicates the effect estimate of individual articles with their 95% CI. Size of squares is proportional to the weight of each paper in the meta-analysis. In this plot, papers are indicated in the order of first author’s names and publication date (based on a random effects model).
Each square indicates the effect estimate of individual articles with their 95% CI. Size of squares is proportional to the weight of each paper in the meta-analysis. In this plot, papers are indicated in the order of first author’s names and publication date (based on a random effects model).

**Fig 4.** Forest Plot of the prevalence of cardiovascular disease in COVID-19 patients.
Fig5. Begg’s funnel plot for publication bias
Fig 6. The association between prevalence of risk factors for COVID-19 and sample size, using Meta regression.
Highlights:

- The most prevalent risk factors among patients with COVID-19 were hypertension, diabetes, cardiovascular disease, and chronic kidney disease.
- The most common symptoms among individuals who had COVID-19 infection were fever, cough, fatigue or myalgia, dyspnea, and diarrhea.
- The mean age of the patients with COVID-19 infection was 56.49.
- If the patient is an elderly male with underlying diseases, he is more likely to have severe disorders or even face to death.